Literature DB >> 24964974

Impact of variant histology on disease aggressiveness and outcome after nephroureterectomy in Japanese patients with upper tract urothelial carcinoma.

Shigeru Sakano1, Hideyasu Matsuyama, Yoriaki Kamiryo, Shigeaki Hayashida, Norio Yamamoto, Yoshitaka Kaneda, Takahito Nasu, Yoshikazu Baba, Tomoyuki Shimabukuro, Akinobu Suga, Mitsutaka Yamamoto, Akihiko Aoki, Kimio Takai, Satoru Yoshihiro, Kazuo Oba.   

Abstract

BACKGROUND: Patients with urinary bladder urothelial carcinoma (UC) with variant histology have features of more advanced disease and a likelihood of poorer survival than those with pure UC. We investigated the impact of variant histology on disease aggressiveness and clinical outcome after radical nephroureterectomy (RNU) in Japanese patients with upper tract UC (UTUC). Information on variant histology might guide appropriate patient selection for adjuvant therapy after RNU.
METHODS: We enrolled 502 UTUC patients treated with RNU in this retrospective cohort study, and analyzed associations of variant histology with clinicopathological variables and disease-specific survival.
RESULTS: The median follow-up was 41.4 months. A total of 60 (12.0 %) UTUC patients had variant histology. UTUC with variant histology was significantly associated with advanced pathological T stage (pT ≥ 3), higher tumor grade (G3), and more lymphovascular invasion (P < 0.0001). Variant histology in all patients was significantly associated with worse disease-specific survival after RNU on univariate analysis (P = 0.0004), but this effect did not remain significant on multivariate analysis. However, variant histology was a significantly independent predictor for disease-specific survival in patients with pT ≥ 3 tumors (P = 0.0095).
CONCLUSIONS: UTUC with variant histology might be a phenotype of high-grade, locally aggressive advanced tumors rather than of systemic disease. Variant histology may be useful for selection of patients with pT ≥ 3 UTUC for adjuvant therapy. Prospective studies in a larger number of patients with a centralized pathological review are needed to confirm our results.

Entities:  

Mesh:

Year:  2014        PMID: 24964974     DOI: 10.1007/s10147-014-0721-3

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  17 in total

1.  Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter.

Authors:  Brian Czito; Anthony Zietman; Donald Kaufman; Uri Skowronski; William Shipley
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

Review 2.  Variant forms of bladder cancer: basic considerations on treatment approaches.

Authors:  Francesc Pons; Anna Orsola; Juan Morote; Joaquim Bellmunt
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

3.  The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma.

Authors:  Simon P Kim; Igor Frank; John C Cheville; R Houston Thompson; Christopher J Weight; Prabin Thapa; Stephen A Boorjian
Journal:  J Urol       Date:  2012-06-14       Impact factor: 7.450

4.  European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update.

Authors:  Morgan Rouprêt; Richard Zigeuner; Juan Palou; Andreas Boehle; Eero Kaasinen; Richard Sylvester; Marko Babjuk; Willem Oosterlinck
Journal:  Eur Urol       Date:  2011-01-14       Impact factor: 20.096

5.  Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study.

Authors:  Kazumasa Matsumoto; Giacomo Novara; Amit Gupta; Vitaly Margulis; Thomas J Walton; Marco Roscigno; Casey Ng; Eiji Kikuchi; Richard Zigeuner; Wassim Kassouf; Hans-Martin Fritsche; Vincenzo Ficarra; Guido Martignoni; Stefan Tritschler; Joaquin Carballido Rodriguez; Christian Seitz; Alon Weizer; Mesut Remzi; Jay D Raman; Christian Bolenz; Karim Bensalah; Theresa M Koppie; Pierre I Karakiewicz; Christopher G Wood; Francesco Montorsi; Masatsugu Iwamura; Shahrokh F Shariat
Journal:  BJU Int       Date:  2011-04-20       Impact factor: 5.588

6.  Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma.

Authors:  Michael Rink; Brian D Robinson; David A Green; Eugene K Cha; Jens Hansen; Evi Comploj; Vitaly Margulis; Jay D Raman; Casey K Ng; Mesut Remzi; Karim Bensalah; Wareef Kabbani; Andrea Haitel; Nathalie Rioux-Leclercq; Charles C Guo; Felix K Chun; Eiji Kikuchi; Wassim Kassouf; Kanishka Sircar; Maxine Sun; Guru Sonpavde; Yair Lotan; Armin Pycha; Pierre I Karakiewicz; Douglas S Scherr; Shahrokh F Shariat
Journal:  J Urol       Date:  2012-06-13       Impact factor: 7.450

7.  Squamous cell carcinoma of the renal pelvis and ureter: incidence, symptoms, treatment and outcome.

Authors:  Sten Holmäng; Subodh M Lele; Sonny L Johansson
Journal:  J Urol       Date:  2007-05-11       Impact factor: 7.450

8.  Defining the clinical target volume for bladder cancer radiotherapy treatment planning.

Authors:  Peter Jenkins; Salim Anjarwalla; Hugh Gilbert; Richard Kinder
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-23       Impact factor: 7.038

Review 9.  The impact of variant histology on the outcome of bladder cancer treated with curative intent.

Authors:  Peter C Black; Gordon A Brown; Colin P N Dinney
Journal:  Urol Oncol       Date:  2008-01-14       Impact factor: 3.498

10.  High-grade urothelial carcinoma of the renal pelvis: clinicopathologic study of 108 cases with emphasis on unusual morphologic variants.

Authors:  Delia Perez-Montiel; Paul E Wakely; Ondrej Hes; Michal Michal; Saul Suster
Journal:  Mod Pathol       Date:  2006-04       Impact factor: 7.842

View more
  6 in total

1.  Impact of Adjuvant Chemotherapy on Variant Histology of Upper Tract Urothelial Carcinoma: A Propensity Score-Matched Cohort Analysis.

Authors:  Chi-Wen Lo; Wei-Ming Li; Hung-Lung Ke; Yi-Huei Chang; Hsi-Chin Wu; I-Hsuan Alan Chen; Jen-Tai Lin; Chao-Yuan Huang; Chung-Hsin Chen; Jen-Shu Tseng; Wun-Rong Lin; Yuan-Hong Jiang; Yu-Khun Lee; Chung-You Tsai; Shiu-Dong Chung; Thomas Y Hsueh; Allen W Chiu; Yeong-Chin Jou; Ian-Seng Cheong; Yung-Tai Chen; Jih-Sheng Chen; Bing-Juin Chiang; Chih-Chin Yu; Wei Yu Lin; Chia-Chang Wu; Chuan-Shu Chen; Han-Yu Weng; Yao-Chou Tsai
Journal:  Front Oncol       Date:  2022-04-22       Impact factor: 5.738

2.  Prognostic significance of urothelial carcinoma with divergent differentiation in upper urinary tract after radical nephroureterectomy without metastatic diseases: A retrospective cohort study.

Authors:  Chuan Qin; En-Li Liang; Zhi-Yong Du; Xiao-Yu Qiu; Gang Tang; Fei-Ran Chen; Bo Zhang; Da-Wei Tian; Hai-Long Hu; Chang-Li Wu
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

3.  Challenging Visualization of Sentinel Lymph Nodes in Upper Urinary Tract Urothelial Carcinoma.

Authors:  Wojciech Polom; Wojciech Cytawa; Anna Polom; Mikołaj Frankiewicz; Edyta Szurowska; Piotr Lass; Marcin Matuszewski
Journal:  J Clin Med       Date:  2021-11-23       Impact factor: 4.241

Review 4.  Impact of pathological factors on survival in patients with upper tract urothelial carcinoma: a systematic review and meta-analysis.

Authors:  Gopal Sharma; Anuj Kumar Yadav; Tarun Pareek; Pawan Kaundal; Shantanu Tyagi; Sudheer Kumar Devana; Shrawan Kumar Singh
Journal:  Int Braz J Urol       Date:  2022 May-Jun       Impact factor: 3.050

5.  Impact of Variant Histology on Clinical and Pathological Outcomes in Patients with the Upper Urinary Tract Urothelial Carcinoma.

Authors:  Meylis Artykov; Hakan Bahadır Haberal; Mesut Altan; Kemal Kosemehmetoglu; Sertac Yazici; Haluk Ozen; Bulent Akdogan
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2022-06-28

6.  The systemic inflammation-based Glasgow Prognostic Score as a powerful prognostic factor in patients with upper tract urothelial carcinoma.

Authors:  Teruo Inamoto; Hideyasu Matsuyama; Shigeru Sakano; Naokazu Ibuki; Kiyoshi Takahara; Kazumasa Komura; Tomoaki Takai; Takuya Tsujino; Yuki Yoshikawa; Koichiro Minami; Kazuhiro Nagao; Ryo Inoue; Haruhito Azuma
Journal:  Oncotarget       Date:  2017-11-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.